Animal & Plant Derived Vaccines


It has been about 30 years since the first plant engineering technology was established. Although the concept of plant-based pharmaceuticals or vaccines motivates us to develop practicable commercial products using plant engineering, there are some difficulties in reaching the final goal: to manufacture an approved product. At present, the only plant-made vaccine approved by the United States Department of Agriculture is a Newcastle disease vaccine for poultry that is produced in suspension-cultured tobacco cells. The progress toward commercialization of plant-based vaccines takes much effort and time, but several candidate vaccines for use in humans and animals are in clinical trials. This review discusses plant engineering technologies and regulations relevant to the development of plant-based vaccines and provides an overview of human and animal vaccines currently under clinical trials.


  • Bovine and porcine products
  • Chicken embryos and embryonated eggs
  • Plants as bioreactors
  • Chloroplast-derived protozoan antigens
  • Chloroplast-derived autoantigens

Related Conference of Animal & Plant Derived Vaccines

May 30-31, 2024

World congress on Immunology and Virology Diseases

Vienna, Austria
August 01-02, 2024

44th Global Summit and Expo on Vaccines & Immunology

Montreal, Canada
September 09-10, 2024

4th International Conference on Vaccine Research

Madrid, Spain
November 28-29, 2024

6th World Congress on Vaccine and Immunology

Paris, France

Animal & Plant Derived Vaccines Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in